Topical imiquimod 5% as an alternative therapy in periocular basal cell carcinoma in two patients with surgical contraindication

Arch Soc Esp Oftalmol. 2017 Feb;92(2):93-96. doi: 10.1016/j.oftal.2016.07.002. Epub 2016 Sep 3.
[Article in English, Spanish]

Abstract

Clinical cases: The cases are presented of two patients with periocular basal cell carcinoma of the eyelid who received topical imiquimod 5%, with a good response. Both had a functional state that contraindicated surgical treatment.

Conclusion: Imiquimod cream 5% was shown to be an effective alternative to surgical treatment of periocular basal cell carcinoma, especially in those cases where surgery is not possible.

Keywords: Basal cell carcinoma; Carcinoma basocelular; Casos desfavorables; Imiquimod; Periocular tumors; Topical treatment; Tratamiento tópico; Tumores perioculares; Unfavourable cases.

Publication types

  • Case Reports

MeSH terms

  • Acquired Immunodeficiency Syndrome / complications
  • Aminoquinolines / adverse effects
  • Aminoquinolines / therapeutic use*
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Basal Cell / drug therapy*
  • Contraindications, Procedure
  • Eyelid Neoplasms / drug therapy*
  • HIV-Associated Lipodystrophy Syndrome / complications
  • Humans
  • Imiquimod
  • Male
  • Middle Aged
  • Plastic Surgery Procedures
  • Remission Induction
  • Skin Ulcer / chemically induced
  • Surgical Flaps

Substances

  • Aminoquinolines
  • Antineoplastic Agents
  • Imiquimod